European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery

Abstract

MethodsThe European Society of Gynaecological Oncology council nominated an international multidisciplinary development group made of practicing clinicians who have demonstrated leadership and interest in the care of ovarian cancer (20 experts across Europe). To ensure that the statements are evidence based, the current literature identified from a systematic search has been reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group (expert agreement). The guidelines are thus based on the best available evidence and expert agreement. Before publication, the guidelines were reviewed by 66 international reviewers independent from the development group including patients representatives.ResultsThe guidelines cover preoperative workup, specialized multidisciplinary decision making, and surgical management of diagnosed epithelial ovarian, fallopian tube, and peritoneal cancers. The guidelines are also illustrated by algorithms.

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

“…Based on previously described examinations, in 2017 ESGO formulated recommendations on contraindications to UDS related to tumour spread 190. Patient-specific factors (eg, co-existing illnesses, age, WHO PS) should also be considered in the pre-operative assessment of operability 174 179.…”

“…Patients are not candidates for primary surgery (according to ESGO 2017 recommendations190) if the following spread of disease, among other factors, is present:…”

Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis

“…To date, the origin of PC after RRSO is unclear and might involve a de novo primary tumor or progression from STIC. In addition, there are no standardized guidelines for staging operations or adjuvant postoperative treatment and follow-up of patients with isolated STIC, with one exception [88]. The results of a systematic review suggest that additional treatment (staging and/or chemotherapy) after RRSO was associated with a lower risk of recurrence [55].…”

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

“…Based on previously described examinations, in 2017 ESGO formulated recommendations on contraindications to UDS related to tumour spread [190]. Patient-specific factors (e.g.…”